Seeking Alpha·Sep 16, 2026
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptVericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel's revenue momentum is accelerating, with 22.5% YoY growth in 2026Q2 and gross margin expansion to 72.8%, driven by strong demand for its cell therapy products. The balance sheet is de-risking, as debt-to-equity fell to 0.25 and cash rose to $125.4M, wh...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.04+238.2% vs -$0.03 | $77M+6.5% vs $73M |
Q2 2026 May 7, 2026 | -$0.12+20.0% vs -$0.15 | $68M+7.5% vs $64M |
Q1 2026 Feb 26, 2026 | $0.45+0.0% vs $0.45 | $93M+2.1% vs $91M |
Q4 2025 Nov 6, 2025 | $0.10+600.0% vs -$0.02 | $68M-27.2% vs $93M |
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,400 shares of the biotechnology company's stock, valued at approximately $596,000. Several other hedge funds and other institutional investors also recently
Benchmark VCEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vericel Corporation (VCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.15 | $2.05B | 125.47 | 16.45% | 5.98% | 5.11% | — | |
| $10.79 | $999.26M | -7.60 | 144.57% | 19.87% | 283.85% | — | |
| $2.56 | $279.54M | -1.27 | — | — | -5.76% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — | |
| $31.80 | $1.89B | -4.47 | 48.03% | -418.24% | -35.67% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — |
Vericel Corporation (VCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vericel Corporation (VCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 18, 2026·SEC
May 7, 2026·SEC
Get notified when VCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vericel Corporation (VCEL) stock FAQ — growth, dividends, profitability & financials explained
Vericel Corporation (VCEL) reported $306.3M in revenue for fiscal year 2025. This represents a 19044% increase from $1.6M in 1996.
Vericel Corporation (VCEL) grew revenue by 16.5% over the past year. This is strong growth.
Yes, Vericel Corporation (VCEL) is profitable, generating $24.2M in net income for fiscal year 2025 (6.0% net margin).
Vericel Corporation (VCEL) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
Vericel Corporation (VCEL) generated $49.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
